Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Oligodendroglioma

Oligodendroglioma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Oligodendroglioma

4 trials tracked for Oligodendroglioma.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4
  1. Phase 2 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed
  2. Phase 2 Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Completed
  3. Phase 2 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) Completed
  4. Phase 2 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Specific clinical and radiological features may identify risk for leptomeningeal dissemination in oligodendroglioma
Oncology Sys. Review
Specific clinical and radiological features may identify risk for leptomeningeal dissemination in oligodendroglioma Risk Markers Linked to Spread of Oligodendroglioma in Spinal Fluid
This scoping review of 15 studies identifies several indicators associated with leptomeningeal dissemination (LMD) in patients with oligoden…
Identifying specific markers like high Ki-67 levels and ventricular involvement may help doctors track the spread of certain brain tumors.
Frontiers Jun 16, 2026